Stocklytics Platform
Asset logo for symbol CRSP
CRISPR Therapeutics AG
CRSP57
$45.49arrow_drop_up0.28%$0.13
Asset logo for symbol CRSP
CRSP57

$45.49

arrow_drop_up0.28%

Income Statement (CRSP)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$151.26M-$140.58M$69.58M-$137.33M-$95.22M
EBITDA-$146.41M-$135.75M$74.48M-$132.41M-$90.26M
gross Profit-$56.45M-$51.29M$180.00M-$23.42M$25.36M
NET Income-$126.40M-$116.59M$89.34M-$112.15M-$77.74M
total Revenue$517.00K$504.00K$200.00M$0.00$70.00M

Balance Sheet (CRSP)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$253.16M-$472.50M-$150.84M-$286.17M-$199.62M
stockholders Equity$1.98B$2.08B$1.88B$1.72B$1.81B
total Assets$2.33B$2.43B$2.22B$2.08B$2.19B
total Debt$231.30M$234.92M$238.63M$241.58M$245.17M
total Liabilities$358.90M$355.08M$346.76M$359.03M$380.98M

Cash Flow (CRSP)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow-$466.00K$305.93M$38.93M$1.55M$16.76M
free Cash Flow-$96.28M$109.03M-$96.81M-$41.97M-$136.80M
investing Cash Flow----$216.92M
operating Cash Flow-$95.58M$109.75M-$96.07M-$39.85M-$133.24M

CRISPR Therapeutics AG (CRSP) Financials

The income statement of CRISPR Therapeutics AG (CRSP) provides a comprehensive overview of the company's financial performance. It shows the revenue generated by the company, as well as the costs and expenses incurred. The income statement includes various key figures, such as gross profit, operating income, and net income. These figures reflect the profitability of the company and its ability to generate profits from its operations. Additionally, the income statement also provides information on earnings before interest and taxes (EBIT) and earnings before interest, taxes, depreciation, and amortization (EBITDA).
The balance sheet of CRISPR Therapeutics AG (CRSP) provides a snapshot of the company's financial position at a specific point in time. It shows the company's assets, liabilities, and stockholders' equity. The balance sheet is divided into two main sections: assets and liabilities. The assets section includes cash, cash equivalents, and other assets, while the liabilities section includes debt and other liabilities. The balance sheet provides valuable information about the company's liquidity, solvency, and the value of its investments. Furthermore, it also shows the company's net debt, which is calculated by subtracting cash and cash equivalents from total debt. The stockholders' equity represents the owners' interest in the company and is calculated by subtracting total liabilities from total assets.
The cash flow statement of CRISPR Therapeutics AG (CRSP) provides information about the company's cash inflows and outflows during a specific period. It includes three main sections: operating activities, investing activities, and financing activities. The operating activities section shows the cash generated or used in the company's core operations, such as revenue from sales and payments to suppliers. The investing activities section shows the cash used for acquisitions, investments in property and equipment, and other long-term assets. The financing activities section shows the cash generated or used from activities such as issuing or repurchasing stock, borrowing or repaying debt, and paying dividends. The cash flow statement is crucial in assessing the company's ability to generate cash and its overall financial health. Lastly, the statement provides information on free cash flow, which is calculated by subtracting capital expenditures from operating cash flow. Free cash flow represents the cash available to the company after investing in its core operations and maintaining its assets.
add CRISPR Therapeutics AG to watchlist

Keep an eye on CRISPR Therapeutics AG

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media